Market cap: $
Exchange: NAS
Sector: Health Technology
Mirati Therapeutics, Inc. is a clinical-stage oncology company. The firm engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.
Company Name
Mirati Therapeutics Inc
Average Volume (10 days)
0
Average Volume (30 days)
0
Moving Average (50 days)
$0
Moving Average (200 days)
$0
Ex-Divided Date
n/a
Dividend Yield
0
P/E Ratio
0
Market Cap
0
Shares Outstanding
70,147,706
52-Week High Split Adjust Only
0
52-Week Low Split Adjust Only
0
Employee Count
593
Beta
0
Next Earnings Date
TTM Dividend Rate Per Share
0
Past 5 days
0%
Past 30 days
0%
Past 3 months
0%
Past 6 months
0%
Past year
0%
Past 2 years
0%
Past 5 years
0%
Max % Change
0%
| Name | Ticker | Price/Sales (ttm) | Price/Book (ttm) | Forward P/E | PEG Ratio | EV/Revenue |
|---|---|---|---|---|---|---|
| Mirati Therapeutics Inc | MRTX | 619.54 | 6.46 | -15.1 | 619.54 | 521.52 |
| Peer Avg | N/A | 2.23 | 4.53 | 14.1 | 2.23 | 2.39 |
| AMGEN Inc. | AMGN | 5.43 | 14.65 | 14.6 | 5.43 | 6.31 |
| Alkermes plc | ALKS | 3.48 | 3.46 | 44.8 | 3.48 | 3.25 |
| Aldeyra Therapeutics Inc | ALDX | n/a | n/a | -3.1 | n/a | n/a |